FibroGen Inc (FGEN)

[Monksdream]

FGEN 10Q due MONDAY 2/24

[chumfm]

Stock is worth $2.00 plus now,when deal is done it will be worth $4.00 cash alone with no debt.At that point it will be worth $8 to $10 bucks.This has a lot more to go.M&M are holding this down to get in,then this will fly.Good luck and good trading.

[TrendTrade2016]

WOULD NOT TOUCH IT NOW

[SwingSensei]

MRSN is looking like it has found the bottom & wants to uptrend. Getting a starter position here

[SwingSensei]

TUYA is about to break 4.00

[TrendTrade2016]

CHART IS GOOD ON GOSS

[SwingSensei]

GOSS is looking to run!

[SwingSensei]

TUYA looking to hit a new 52wk high today

[ollik78]

1$ is coming today or next days 

[TrendTrade2016]

FGEN BLOWING UP HUGE NEWS

[81vette]

3m short, cover bitches

[81vette]

Got the .71 dip

[glenn1919]

FGEN.....................................https://stockcharts.com/h-sc/ui?s=FGEN&p=W&b=5&g=0&id=p86431144783

[georgie18]

FGEN...Adding 54s here...🥳

georgie18

Member Level
Re: None

Thursday, January 09, 2025 10:24:58 AM

Post#
670924
of 672174
FGEN...65...🥳... https://schrts.co/epTBTrZY ...Looking for the 200ma Breakout and a Cup formation to $1.50 range...Open Gap in the .90 range...

[georgie18]

FGEN...65...🥳... https://schrts.co/epTBTrZY ...Looking for the 200ma Breakout and a Cup formation to $1.50 range...Open Gap in the .90 range...

[glenn1919]

FGEN.........................https://stockcharts.com/h-sc/ui?s=FGEN&p=W&b=5&g=0&id=p86431144783

[gail]

wow.

[Triple nickle]

Last gap to fill 1.14

[gail]

hopped back out yesterday but ….

…

watching for a better re entry.

[gail]

and going back up again.

[gail]

after hours low vol pull back but i think we see new highs tomorrow

[gail]

here we go!

[gail]

appears the dip is over, lets do this!

[gail]

grabbed some but still dipping.

[glenn1919]

FGEN........................https://stockcharts.com/h-sc/ui?s=FGEN&p=W&b=5&g=0&id=p86431144783

[Lilman72003]

thanks I guess? lol

[Triple nickle]

That’s good to hear you stuck it out
Take your profits and do the same thing again. Go buy yourself a 100.00 button down shirt with your start up money now.

[Lilman72003]

Cashed out here. In below .40 and exited above $1.50

Basically made my money 4X here. That’s called beating The Street.

[Lilman72003]

Taking profit

[Lilman72003]

turned .30s into 90 and still awaiting volume

[Monksdream]

FGEN new 52 week low

[Lilman72003]

Insane criminal shorting and manipulation

[Lilman72003]

She’s ready

[Monksdream]

FGEN new 52=week low

[Monksdream]

FGEN new 52 week low

[Monksdream]

FGEN new 52 week low

[Monksdream]

FGEN new 52 week low

[Monksdream]

FGEN new 52 week low

[Monksdream]

FGEN new 52 week low

[TheFinalCD]

2.67 AH

[nuclear profitz]

dead cat bounce?

[girlfriend]

Bought my first batch of this FGEN just now at 11.36

Here to win!

[Giovanni]

lol Good luck

[paulsbest]

I bought, sold with a small profit and then bought again. and now ?

What should the reference to tax loss selling tell me other than that I don't care what short-sellers say ?

i find out about the sales expectations for china and europe beforehand. I act accordingly, not on the basis of anonymous advice.

[Giovanni]

Do not even think of buying till Tax loss selling ensues

[paulsbest]

FGEN NEWS today:

Todays News, reaf this

FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

[paulsbest]

FGEN - China & Europe vote for Roxa, next trials in pipe!

China market will rock for FGEN, read this

The FDA recently rejected AstraZeneca and FibroGen's roxadustat for the treatment of anemia in patients with chronic kidney disease.

Even if roxadustat is never approved in the U.S., the Chinese market alone should be big enough to drive solid sales growth.

[conix]

FibroGen Kidney-Disease Drug Set Back as FDA Panel Urges Rejection

Dan Weil

FibroGen shares slumped on Friday after an FDA advisory committee recommended against approval for roxadustat, the company's drug for anemia stemming from chronic kidney disease.

a person sitting on a table: FibroGen Kidney-Disease Drug Set Back as FDA Panel Urges Rejection© TheStreet FibroGen Kidney-Disease Drug Set Back as FDA Panel Urges Rejection
Shares of the San Francisco company recently traded at $15.89, down 36%. It had dropped 43% in the six months through Thursday.

The Food and Drug Administration isn't required to follow an advisory committee's vote, but it generally does.

"While we are disappointed with today's outcome, we believe the scientific evidence supports roxadustat approval in the U.S. and will work with the FDA as it completes its review of the new drug application," FibroGen Chief Executive Enrique Conterno said in a statement.

Roxadustat has been approved in China, Japan, Chile, and South Korea.

In other health news this week, the Centers for Medicare and Medicaid Services proposed reimbursement rules that include a 20% cut in physician payments for the Urolift service of medical device company Teleflex .

UroLift is Teleflex's system to treat enlarged prostate. The reimbursement guideline applies to procedures performed in doctors' offices.

The news was a "negative surprise," said Wells Fargo analyst Shagun Singh, according to Bloomberg. He said 30% of UroLift sales come from doctors' offices.

To be sure, Piper Sandler analyst Matt O'Brien said, according to Bloomberg, that while the reimbursement move on UroLift is sizable and will hurt doctors' profitability, it shouldn't greatly curb Teleflex's revenue and growth rate. He affirmed his overweight rating on the stock.

[conix]

Chart

[conix]

Is Fibrogen Still a Buy Following Data Analysis Faux Pas? Analyst Weighs In

Marty Shtrubel

Apr 08, 2021

No one likes being given the wrong information. Investors reacted in dismay and sent Fibrogen (FGEN) shares deep into the red following the company’s embarrassing announcement. The biotech company said it had gotten the analysis for its therapy for sufferers of anemia related to chronic kidney disease, well, wrong.

The company said that the data from the late-stage study of roxadustat had “included post-hoc changes to the stratification factors.” The data was used instead of the original stratification plan, in presentations and several press releases last year. Leerink analyst Geoff Porges says it was also “presumably” used in the submission to the FDA.

Management said it was carrying out an “internal review to ensure such issues do not occur in the future.”

The major “oops,” says Porges, is nothing less than stunning.

“The re-statement reduced the benefit from roxa vs controls in every case, erased the appearance of superiority over ESAs in incident dialysis patients, and increased the apparent risk of a negative effect of roxa on CV safety in non-dialysis patients,” the analyst said. “It’s not clear to us whether the company previously mis-presented, or mis-represented, the results of the analysis, but either way this disclosure, long after the NDA had been submitted, and after both PDUFA dates have passed, raises questions about the reception that the company will get when they appear at the newly announced FDA Cardio Renal Advisory Committee meeting on July 15.”

The disclosure is also sure to raise several questions amongst investors. Does roxadustat still have any chance of approval? Will it affect the company’s partnership with AstraZeneca? Will management survive?

As far as Roxadustat is concerned, Porges anticipates one of two likely outcomes. If, as management has suggested, the FDA was informed of the issue and already aware of the “different statistical analyses,” then it “could approach the review without prejudice.” The drug could then even be granted approval by the end of the summer.

On the other hand, if the FDA has only recently been notified of the issue, then Porges says, there is the “real possibility that the agency will require a complete audit of all of the trial results, endpoints and analyses in the database, which could require many months.”

Porges takes the prudent approach and now does not expect approval until 1Q22.

Interestingly, though, Porges sticks to an Outperform (i.e. Buy) rating, and while the price target is reduced from $64 to $56, the revised figure still implies upside of a hefty 198%. (To watch Porges’ track record, click here)

Overall, TipRanks analysis of 9 analyst ratings shows an indecision between the bulls and the naysayers on FGEN: 4 suggest Buy, 4 say Hold, and only one recommends Sell. Importantly, the 12-month average price target stands at $47.17, marking nearly 151% in upside potential from where the stock is currently trading. (See FGEN stock analysis on TipRanks)